Royalty Report: Drugs, Therapeutic, Disease – Collection: 118


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 118

License Grant
The Licensor granted the Licensee exclusive rights to commercialize Fenoglide® (fenofibrate) prescription products in the U.S.

Under the terms of the License Agreement, the Licensee is responsible for commercial, manufacturing and regulatory activities for Fenoglide.

License Property
Fenoglide is approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce elevated low-density lipoprotein-cholesterol (LDL-C), total cholesterol, triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein-cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia. Fenoglide is also indicated as an adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia.  Fenofibrate is also effective in the treatment of Diabetes Type II and metabolic syndrome.

In connection with the assumption of these responsibilities, the Licensor's existing Agreements relating to the manufacture and supply of Fenoglide, as well as existing inventory, have been assigned to the Licensee.

The Licensee has agreed to use commercially reasonable efforts to commercialize Fenoglide within the U.S. In addition, prior to the entry of any generic version of Fenoglide, the Licensee is required to provide certain minimum detailing efforts and sales and marketing expenditures.

During the term of the License Agreement, the Licensor is not permitted to, directly or indirectly, develop, manufacture or commercialize any fenofibrate products for human use in the U.S

The Licensee also has exclusive rights to use the Fenoglide trademark in the U.S.


Issue Date/ Filing Date

Patent Number/ Application No.





Solid Dosage Form Comprising a Fibrate




Solid Dosage Form Comprising a Fibrate




Solid Dosage Form Comprising a Fibrate




Solid Dosage Form Comprising a Fibrate




Tablet Comprising a Fibrate


12APR2006 (PCT)


Tablet Comprising a Fibrate

The present invention relates to novel solid dosage forms and pharmaceutical compositions comprising a fibrate, notably fenofibrate. Particularly, the invention discloses solid dosage forms having increased bioavailability. The solid dosage forms of the invention comprise fibrate dissolved in a suitable vehicle or mixture of vehicles. The dosage forms are especially intended for oral use and exhibit excellent storage stability, i.e. are stable. The invention also relates to methods for preparation of the solid dosage forms and pharmaceutical compositions and the use thereof.

“Product Trademarks” means (a) Fenoglide® and all other Trademarks used by Licensor.

Field of Use
Field means the prevention, palliation or treatment of any condition, indication or diseases in humans.

IPSCIO Record ID: 248789

License Grant
For Licensees Right to Licensor Clinical Data for Canada and Mexico, Licensor shall grant the French Licensee access to the Licensor Clinical Data for use solely in Canada and Mexico in order that Licensee may use such Licensor Clinical Data for the limited purpose of obtaining registrations with the appropriate Canadian and Mexican regulatory authorities in order to allow License to commercialize the Product in such country.
License Property
The Clinical Data is all preclinical, clinical, technical and other information relative to the clinical program, data, analyses, studies or similar information, including, without limitation, all Intellectual Property, generated or developed by or on behalf of the parties after the date hereof as a result of or in connection with the Product Development Program and the clinical trials conducted by Licensor.

Active Pharmaceutical Ingredient means the raw non-micronized fenofibrate used in the Product manufactured by a party other than Licensor or any of its Affiliates.

Product means a product composed of or containing micronized fenofibrate, in any dosage form, including encapsulated or bulk beads, granules or similar presentations, including, without limitation, the fenofibrate product developed by Licensor for Licensee pursuant to this Agreement and the Product Development Program.

Antara (fenofibrate) is a lipid-regulating agent called a fibrate used to treat high cholesterol and high triglyceride levels.

Field of Use
The products are for cardiovascular use.

IPSCIO Record ID: 203313

License Grant
Licensor grants an exclusive, even as to Licensor, world-wide license under the Patent Rights and the Know-How to develop, make, have made, use, sell, have sold, offer for sale, import or otherwise commercialize Licensed Products and Improvements in the Field.
License Property
The Compounds shall mean doxepin, amitriptyline, trimipramine, trazodone and nortriptyline, as well as any respective prodrugs, hydrates, salts, esters, isomers, polymorphs or analogues thereof.

'Patent Rights' shall mean: (i) U.S. Patent Nos. 5,502,047, 5,643,897, 6,211,229 and 6,344,487

Field of Use
The Field shall mean the prevention, treatment or control of insomnia, and any other use of the Compounds within the Ranges.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.